Hannah Barman

Hannah Barman

Auto-generated profile, based on publicly available information

Hannah Barman

Department of Biomedical Research, Nference, Inc., Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
HBHannah Barman
Hannah Barman
SVSriram Venkateswaran
Sriram Venkateswaran
ASAntonio Del Santo
Antonio Del Santo
UYUnice Yoo
Unice Yoo
ESEli Silvert
Eli Silvert
RMRajat Mohindra
Rajat Mohindra
PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in the real-world data setting is critical for characterizing the benefit/risk profile of ICI therapies beyond the clinical trial population. Diagnosis codes, such as International Classification of Diseases codes, do not comprehensively illustrate a patient's care journey and offer no insight into drug-irAE causality. This study aims to capture the relationship between ICIs and irAEs more accurately by using augmented curation (AC), a natural language processing–based innovation, on unstructured data in electronic health records. METHODS: In a cohort of 9,290 patients treated with ICIs at Mayo Clinic from 2005 to 2021, we compared the prevalence of irAEs using diagnosis codes and AC models, which classify drug-irAE pairs in clinical notes with implied textual causality. Four illustrative irAEs with high patient impact—myocarditis, encephalitis, pneumonitis, and severe cutaneous adverse reactions, abbreviated as MEPS—were analyzed using corticosteroid administration and ICI discontinuation as proxies of severity. RESULTS: For MEPS, only 70% (n = 118) of patients found by AC were also identified by diagnosis codes. Using AC models, patients with MEPS received corticosteroids for their respective irAE 82% of the time and permanently discontinued the ICI because of the irAE 35.9% (n = 115) of the time. CONCLUSION: Overall, AC models enabled more accurate identification and assessment of patient impact of ICI-induced irAEs not found using diagnosis codes, demonstrating a novel and more efficient strategy to assess real-world clinical outcomes in patients treated with ICIs.

1 January 2026 in The Breast Journal
Verified
Journal Article
Open access
AIAnushree R. Iyengar
Anushree R. Iyengar
EDErinn P. Downs
Erinn P. Downs
SMSandhya Mehta
Sandhya Mehta
NRNivedita Rangarajan
Nivedita Rangarajan
MWMichele Sue-Ann Woo
Michele Sue-Ann Woo
HBHannah Barman
Hannah Barman
Historically, HER2 status in invasive breast cancer has been categorized as HER2‐positive (IHC 3+, IHC 2+/ISH+) or HER2‐negative (IHC 0, IHC 1+, IHC 2+/ISH‐). Patients meeting IHC 0 with membrane staining (HER2‐ultralow) criteria may benefit from HER2‐targeted therapies such as trastuzumab deruxtecan. This cohort study assessed the prevalence of HER2‐ultralow expression by re‐scoring HER2 IHC slides using Mayo Clinic electronic health record data. Three hundred patients with advanced breast cancer (Stages III‐IV) and documented HER2 IHC 0 status (January 2017–March 2023) were identified. One slide per patient was digitized and independently re‐scored by two Mayo Clinic pathologists following the 2023 ASCO‐CAP guidelines, including tumor staining percentage to denote HER2‐ultralow status. A sensitivity analysis was performed by a third independent pathologist. The re‐scored patients had a mean age of 57.7 years (SD = 13.6). Most samples (95%, n = 285) remained scored IHC 0 by at least one pathologist; 60% of these met HER2‐ultralow criteria per at least one pathologist. HER2‐ultralow prevalence ranged from 43% to 45% per pathologist, with 57% overall interpathologist concordance. Samples with no observable staining comprised most of the concordant cases. Treatment patterns were similar between HER2‐ultralow and no‐staining groups; however, time to treatment failure (TTF) varied between groups across lines of therapy (LOT). In HR− positive cohorts, median TTF for LOT1 was 7.73 months in patients with HER2‐ultralow versus 9.43 months with no observable IHC staining. In HR− negative cohorts, median TTF was 5.00 months for HER2‐ultralow versus 3.17 months with no observable IHC staining. Similar TTF trends were observed in LOT2‐LOT3. Approximately three in five samples originally classified as IHC 0 met HER2‐ultralow criteria, suggesting many patients may benefit from HER2‐directed therapy if reclassified. These findings highlight potential challenges of identifying HER2‐ultralow expression and suggest the need for enhanced pathologist training, adherence to best practices, and integration of digital pathology and artificial intelligence solutions. Trial Registration: ClinicalTrials.gov_identifier: NCT03734029